» Articles » PMID: 18772725

Left-right Asymmetry in Hearing Loss Following Cisplatin Therapy in Children--the Left Ear is Slightly but Significantly More Affected

Overview
Journal Ear Hear
Date 2008 Sep 6
PMID 18772725
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Bilateral symmetric high frequency hearing loss is regarded as one of the main characteristics of cisplatin-induced ototoxicity. Hair-cell damage because of cisplatin is discussed as the leading cause of hearing loss. Our observations in long-term audiological follow-up of children treated with cisplatin did not always show the anticipated symmetry of hearing loss.

Design: Pure-tone audiograms of 55 (34 m, 21 f) children receiving chemotherapy with cisplatin at Muenster university hospital were analyzed. We compared pure tone hearing thresholds, transient evoked otoacoustic emissions levels and distortion product otoacoustic emissions levels before and after chemotherapy with cisplatin.

Results: After therapy, the 55 children showed slightly higher average hearing levels in the range 2000 to 8000 Hz in the left ear. The side difference was significant at 4000, 6000, and 8000 Hz. In girls, the effect was less pronounced than in boys.

Conclusions: This result, on the one hand, indicates that the auditory system is already responding asymetrically at the cochlear level, on the other hand it underscores the need for further research into the pathophysiology of platinum ototoxicity. There are parallels with stronger effects to the left ear in oiseinduced hearing loss as described in literature. Special attention should be given to possible supracochlear pathways of damage. Clinicians should consider that cisplatin associated hearing loss is not necessarily symmetric.

Citing Articles

Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.

Macedo L, Dias Costa E, Carvalho B, Lourenco G, Calonga L, Castilho A Cancers (Basel). 2023; 15(6).

PMID: 36980643 PMC: 10046479. DOI: 10.3390/cancers15061759.


Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review.

DeBacker J, McMillan G, Martchenke N, Lacey C, Stuehm H, Hungerford M J Cancer Surviv. 2023; 17(1):82-100.

PMID: 36729346 PMC: 11727884. DOI: 10.1007/s11764-022-01315-8.


Distortion Product Otoacoustic Emissions (DPOAEs) In Tinnitus Patients.

Alshabory H, Gabr T, Kotait M Int Arch Otorhinolaryngol. 2022; 26(1):e046-e057.

PMID: 35096158 PMC: 8789488. DOI: 10.1055/s-0040-1722248.


Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma.

Gupta T, Mohanty S, Kannan S, Jalali R Neurooncol Pract. 2019; 1(3):86-93.

PMID: 31386031 PMC: 6657387. DOI: 10.1093/nop/npu017.


A Review of Cisplatin-Associated Ototoxicity.

Paken J, Govender C, Pillay M, Sewram V Semin Hear. 2019; 40(2):108-121.

PMID: 31036989 PMC: 6486385. DOI: 10.1055/s-0039-1684041.